Antihypertensive drug first choice should be tempered by "special considerations" -- JAMA.
ANTIHYPERTENSIVE DRUG FIRST CHOICE: "SPECIAL CONSIDERATIONS" should temper the selection, with the "most overriding" consideration being concomitant disease, Norman Kaplan, MD, University of Texas Southwestern Medical Center, and Ray Gifford, MD, Cleveland Clinic Foundation, advise in a special communication published in the May 22/29 Journal of the American Medical Association. Other considerations include demographics (age, sex, race), sexual function and quality of life.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth